HC Wainwright & Co. Reiterates Buy on Poseida Therapeutics, Maintains $20 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Arthur He has reiterated a Buy rating for Poseida Therapeutics (NASDAQ:PSTX) and maintained a $20 price target.
October 17, 2024 | 11:12 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. analyst Arthur He has reiterated a Buy rating for Poseida Therapeutics and maintained a $20 price target, indicating confidence in the company's future performance.
The reiteration of a Buy rating and maintenance of a $20 price target by a reputable analyst suggests positive sentiment and confidence in Poseida Therapeutics' future performance, likely leading to a positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100